HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study

Table 3 Treatment related adverse events

Adverse event	HAIC-LEN-PD1		LEN-PD1		P-value
Adverse event	Any grade	Grade 3–4	Any grade	Grade 3–4	Any grade	Grade 3–4
Neutropenia	45 (43.7%)	12 (11.7%)	6 (9.8%)	1 (1.6%)	< 0.001	0.014
Anaemia	13 (12.6%)	2 (1.9%)	5 (8.2%)	0 (0.0%)	0.381	0.530
Thrombocytopenia	46 (44.7%)	17 (16.5%)	8 (13.1%)	2 (3.3%)	< 0.001	0.011
Fatigue	43 (41.7%)	3 (2.9%)	21 (34.4%)	2 (3.3%)	0.353	0.895
Hypertension	62 (60.2%)	9 (8.7%)	32 (52.5%)	5 (8.2%)	0.333	0.875
Weight loss	41(39.8%)	3 (2.9%)	21 (34.4%)	2 (3.3%)	0.492	0.895
Hypothyroidism	36 (34.9%)	3 (2.9%)	18 (29.5%)	2 (3.3%)	0.473	0.895
Rash	18 (17.5%)	5 (4.9%)	10 (16.4%)	2 (3.3%)	0.859	0.629
Vomiting	43 (41.7%)	10 (9.7%)	8 (13.1%)	1 (1.6%)	< 0.001	0.046
Diarrhea	15 (14.6%)	2 (1.9%)	6 (9.8%)	1 (1.6%)	0.472	0.889
Abdominal pain	62 (60.2%)	10 (9.7%)	12 (19.7%)	2 (3.3%)	< 0.001	0.213
Proteinuria	21 (20.4%)	5 (4.9%)	9 (14.8%)	2 (3.3%)	0.367	0.629
Elevated ALT	62 (60.2%)	21(20.4%)	11 (18.0%)	5 (8.2%)	< 0.001	0.039
Elevated AST	65 (63.1%)	21 (20.4%)	12 (19.7%)	6 (9.8%)	< 0.001	0.078
Hyperbilirubinacemia	45 (43.7%)	18 (17.5%)	15 (24.6%)	3 (4.9%)	0.087	0.020
Hyboalbuminaemia	42 (40.8%)	15 (14.6%)	23 (37.7%)	5 (6.6%)	0.697	0.229
Decreased appetite	38 (36.9%)	10 (2.9%)	20 (32.8%)	3 (4.9%)	0.595	0.895
Elevated creatinine	18 (17.5%)	4 (3.9%)	6 (9.8%)	1 (1.6%)	0.181	0.419
Immune-related hepatitis	5 (4.9%)	2 (1.9%)	2 (3.3%)	1 (1.6%)	0.859	0.889
Immune-related pneumonitis	3 (2.9%)	2 (1.9%)	2 (3.3%)	0 (0.0%)	0.629	0.530
Immune-related dermatitis Immune-related myocarditis	8 (7.8%) 1 (0.9%)	2 (1.9%) 0 (0.9%)	2 (3.3%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	0.246 0.440	0.530 NA

Abbreviations: ALT, alanine aminotransferase; AST, aspartate; NA, notapplicable
Listed are adverse events, as defined by the National Cancer Institute Common Terminology Criteria (version 5.0)

ISSN: 1471-2407